Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Altamira Therapeutics Reports Pricing Of Up To $12M Public Offering; $4M Upfront With Up To Additional $8M Of Aggregate Gross Proceeds Upon Exercise Of Milestone-linked Warrants

Author: Benzinga Newsdesk | September 17, 2024 05:11pm

The company announced the pricing of a public offering of an aggregate of 5.55 million common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5.55 million common shares and Series A-2 common warrants to purchase up to 5.55 million common shares, at a combined public offering price of $0.72 per share (or per pre-funded warrant in lieu thereof) and accompanying Series A-1 common warrant and Series A-2 common warrant. 

Posted In: CYTO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist